MétaCan
Menu
Back to cohort
Record W2050657418 · doi:10.1310/hct1101-39

A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy

2010· review· en· W2050657418 on OpenAlexaff
Janet Raboud, Christina Diong, Andrew Carr, Steven Grinspoon, Kathleen Mulligan, Jussi Sutinen, William Rozenbaum, Rodrigo B. Cavalcanti, Handan Wand, Dominique Costagliola, Sharon Walmsley

Bibliographic record

VenueHIV Clinical Trials · 2010
Typereview
Languageen
FieldMedicine
TopicHIV-related health complications and treatments
Canadian institutionsUniversity Health NetworkUniversity of Toronto
FundersNational Center for Research ResourcesU.S. Public Health ServiceNational Institutes of HealthAmgenNational Institute of Diabetes and Digestive and Kidney DiseasesGilead SciencesNational Institute of Allergy and Infectious DiseasesMedical Research CouncilACT GovernmentBristol-Myers SquibbGlaxoSmithKlineNational Health and Medical Research Council
KeywordsPioglitazoneRosiglitazoneMedicinePlaceboThiazolidinedioneStavudineInternal medicineLipoatrophyBody mass indexZidovudineUrologyEndocrinologyGastroenterologyPharmacologyDiabetes mellitusHuman immunodeficiency virus (HIV)Antiretroviral therapyType 2 diabetesViral loadInsulinImmunologyPathology

Abstract

fetched live from OpenAlex

OBJECTIVE: To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS: Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Generalized estimating equation (GEE) models were used to estimate the treatment effect on changes in limb fat mass. RESULTS: In the combined dataset of 427 patients, the baseline median age was 45 years, 86% were male, 80% were Caucasian, 63% were receiving stavudine (d4T) or zidovudine (AZT), 66% were on protease inhibitors, and median body mass index was 23 kg/m(2). In a univariate GEE model, TZD was associated with an increase in limb fat mass (coeff = 0.14 kg vs placebo, P = .04). In a multivariable GEE model, patients receiving pioglitazone had significantly higher limb fat mass gains (coeff = 0.35 kg, P < or = .01) compared to patients receiving placebo, while patients on rosiglitazone did not (coeff = 0.05 kg, P = .48). Interactions between thymidine analogue use and rosiglitazone and pioglitazone were not significant. CONCLUSIONS: In this meta-analysis, pioglitazone therapy was more effective than placebo to increase limb fat mass whereas rosiglitazone was not significantly better than placebo. The effectiveness of these drugs did not vary according to whether the patients were receiving thymidine analogues.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.017
metaresearch head score (Gemma)0.031
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.017
Threshold uncertainty score0.092

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0170.031
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0170.042
Bibliometrics0.0040.005
Science and technology studies0.0010.001
Scholarly communication0.0040.001
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.642
GPT teacher head0.587
Teacher spread0.055 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations37
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueHIV Clinical TrialsSame topicHIV-related health complications and treatmentsFrench-language works237,207